Investigating BAFF's correlation with autoimmunity and immunodeficiency in MS patients on B-cell therapies, suggesting its potential as a predictive biomarker.
We previously established B-cell activating factor (BAFF) as a biomarker of hypogammaglobinemia in Multiple Sclerosis (MS) patients on ocrelizumab. In this study, we investigate whether BAFF correlates with rates of secondary autoimmunity and immunodeficiency in MS patients on B-cell depleting therapies.
No takes yet. Share an insight, caveat, or question.
Alexeeva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: